Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02751710

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:21.651271+00:00

Published At

2024-01-19T00:00:00+00:00

Record Updated At

2024-01-19

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)", "Stage IIb Breast Cancer (T3N0)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2024-01-19"

protocolSection.identificationModule.nctId

"NCT02751710"

protocolSection.identificationModule.officialTitle

"Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["NA"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4) (protocolSection.conditionsModule.conditions)
• Stage IIb Breast Cancer (T3N0) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.